9 September 2024
\n \n \n \nCardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has secured $6.5M in seed funding led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures.
\n \n\n \n \n19 August 2024
\n \n \n \nOxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.
\n \n\n \n \n11 August 2024
\n \n \n \nCyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Or\u00e9al organised in collaboration with Genopole and Hello Tomorrow.
\n \n\n \n \n15 July 2024
\n \n \n \nNucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.
\n \n\n \n \n7 July 2024
\n \n \n \nAgricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.
\n \n\n \n \n11 June 2024
\n \n \n \nOchre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.
\n \n\n \n \n5 June 2024
\n \n \n \nFormer BioEscalator tenant Alchemab Therapeutics continues to make significant strides in Parkinson's disease research, recently receiving a substantial grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its innovative antibody discovery program.
\n \n\n \n \n17 April 2024
\n \n \n \nThe BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.
\n \n\n \n \n27 October 2022
\n \n \n \nWith Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.
\n \n\n \n \n26 September 2022
\n \n \n \nNucleome Therapeutics has outgrown its space at the BioEscalator and moved to pastures new. The company will continue its growth journey at The Oxford Science Park.
\n \n\n \n \n31 July 2022
\n \n \n \nPepGen is the last of the original cohort of companies that moved into the BioEscalator when it first opened. The new PepGen headquarters in Boston, USA, will manage late-stage preclinical testing and clinical and regulatory functions.
\n \n\n \n \n30 June 2022
\n \n \n \nWinner of OUBT's Biohackathon 2022, part of the Oxford Catalyse Programme, Theraport join the BioEscalator community for three months.
\n \n\n \n \n15 May 2022
\n \n \n \nThe company has moved into the newly refurbished Hayakawa Building at the Oxford Science Park.
\n \n\n \n \n10 May 2022
\n \n \n \nThis research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.
\n \n\n \n \n9 May 2022
\n \n \n \nNucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.
\n \n\n \n \n4 May 2022
\n \n \n \nThe shares are expected to begin trading on the Nasdaq Global Select Market on 6 May 2022 under the symbol \u201cPEPG.\u201d The offering is expected to close on 10 May 2022, subject to the satisfaction of customary closing conditions.
\n \n\n \n \n10 April 2022
\n \n \n \nThe company plans to develop Lilly\u2019s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
\n \n\n \n \n5 April 2022
\n \n \n \nInitiation of Phase 1 Study marks PepGen\u2019s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.
\n \n\n \n \n25 January 2022
\n \n \n \nThe research collaboration will investigate TPOXX\u00ae (tecovirimat) in combination with Bioarchitech\u2019s proprietary vaccinia-based immunotherapy platform in preclinical studies.
\n \n\n \n \n3 January 2022
\n \n \n \nKyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
\n \n\n \n \n